6ag3
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='6ag3' size='340' side='right'caption='[[6ag3]], [[Resolution|resolution]] 2.48Å' scene=''> | <StructureSection load='6ag3' size='340' side='right'caption='[[6ag3]], [[Resolution|resolution]] 2.48Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'> | + | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6AG3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6AG3 FirstGlance]. <br> |
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.48Å</td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.48Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=9XC:3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide'>9XC</scene></td></tr> | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=9XC:3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide'>9XC</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ag3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ag3 OCA], [https://pdbe.org/6ag3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ag3 RCSB], [https://www.ebi.ac.uk/pdbsum/6ag3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ag3 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ag3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ag3 OCA], [https://pdbe.org/6ag3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ag3 RCSB], [https://www.ebi.ac.uk/pdbsum/6ag3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ag3 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| - | == Disease == | ||
| - | [https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[https://omim.org/entry/601709 601709]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref> | ||
| - | == Function == | ||
| - | [https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. | ||
==See Also== | ==See Also== | ||
*[[Urokinase 3D Structures|Urokinase 3D Structures]] | *[[Urokinase 3D Structures|Urokinase 3D Structures]] | ||
| - | == References == | ||
| - | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Buckley B]] | [[Category: Buckley B]] | ||
Current revision
Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide
| |||||||||||
Categories: Large Structures | Buckley B | Huang MD | Jiang LG | Kelso M | Majed H | Ranson M
